InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.27 USD
-0.02 (-6.41%)
Updated Jul 29, 2024 03:59 PM ET
After-Market: $0.27 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for InMed Pharmaceuticals Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 4 | 1 | 0 | 0 |
Cost Of Goods | NA | 3 | 1 | 0 | 0 |
Gross Profit | NA | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 10 | 18 | 10 | 9 |
Income After Depreciation & Amortization | 0 | -8 | -17 | -10 | -9 |
Non-Operating Income | NA | 0 | -1 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -8 | -19 | -10 | -9 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -8 | -19 | -10 | -9 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -8 | -19 | -10 | -9 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -8 | -17 | -10 | -9 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -8 | -17 | -10 | -9 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 2.45 | 0.56 | 0.27 | NA |
Diluted EPS Before Non-Recurring Items | NA | -3.25 | -33.17 | -38.00 | NA |
Diluted Net EPS (GAAP) | NA | -3.25 | -33.17 | -38.00 | -42.75 |
Fiscal Year end for InMed Pharmaceuticals Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1.17 | 1.24 | 0.90 | 2.31 |
Cost Of Goods | NA | 0.88 | 0.92 | 0.88 | 0.74 |
Gross Profit | NA | 0.29 | 0.32 | 0.02 | 1.57 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.08 | 2.03 | 2.64 | 2.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.79 | -1.71 | -2.62 | -0.51 |
Non-Operating Income | NA | 0.07 | 0.23 | 0.09 | 0.18 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.72 | -1.48 | -2.54 | -0.34 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.72 | -1.48 | -2.54 | -0.34 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.72 | -1.48 | -2.54 | -0.34 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 9.61 | 7.97 | 3.33 | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.18 | -0.19 | -0.76 | NA |
Diluted Net EPS (GAAP) | NA | -0.18 | -0.19 | -0.76 | 2.32 |